Renal cell carcinoma: Current status and emerging therapies

Research output: Contribution to journalArticlepeer-review

85 Scopus citations


Renal cell carcinoma (RCC) accounts for about 3% of all adult malignancies and its incidence is increasing. Smoking, obesity, and end-stage renal disease are important risk factors. Localized RCC may be cured with surgical excision. However, over one-third of patients eventually develop metastatic disease. While chemotherapy and radiation therapy are relatively ineffective for RCC, immunotherapy modestly extends survival and may lead to tumor regression and long-term survival in a small minority of patients. Recently, research into the pathology of genetic syndromes associated with RCC has led to remarkable advances in our understanding of the pathogenesis of sporadic RCC. Rational therapeutic agents developed from this understanding have established new treatment paradigms for this disease.

Original languageEnglish (US)
Pages (from-to)299-313
Number of pages15
JournalCancer Treatment Reviews
Issue number3
StatePublished - May 2007


  • Bevacizumab
  • Renal cell carcinoma
  • Sorafenib
  • Sunitinib
  • Targeted therapy
  • Temsirolimus

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Renal cell carcinoma: Current status and emerging therapies'. Together they form a unique fingerprint.

Cite this